PIK3CA and neoplasm: Other studies support that Akt, a member of the PI3K/Akt/MTOR pathway, could also drive tumor resistance to BRAFV600E inhibitors and thus simultaneous inhibition of those two pathways (BRAF and PI3K) is needed [33, 63, 64].